One Cure

The answer to cancer may be walking right beside us.

Donate Today

One Cure for Pets and People

Launched in 2011, the One Cure initiative is founded on the principle that cancer affects all creatures and that treatment breakthroughs come through collaboration between scientists and doctors working with people and animals. This approach is known as comparative oncology and it is the guiding concept of One Cure and the Flint Animal Cancer Center (FACC) at Colorado State University. At FACC, we work to improve prevention, diagnosis and treatment of cancer in pets, and team with the human medical field to translate research findings that will help people with cancer. One Cure’s mission is to advance translational cancer research through comparative oncology clinical trials. One Cure’s goal is to raise awareness and funding to support FACC's clinical trials program and other comparative oncology research.

Progress in the fight against cancer requires knowledge gained from both laboratory and clinical research, which comes together in clinical trials for pets with naturally occurring cancers. These studies aim to bring new, promising treatments to cancer patients, both pets and humans, with the goal of improving outcomes and reducing side effects. At the FACC, we see more than 1,500 new cancer patients every year. Annually, about 100 patients enroll in carefully-monitored clinical trials, each one specific for their cancer type. With owner consent, our canine and feline patients are pioneers in cancer research, helping us move cutting-edge treatments off the laboratory bench and into clinical practice; providing hope to the next generation of animal and human cancer patients. Please take a few minutes to watch the video below to learn more about One Cure. 


The Answer to Cancer May Be Walking Right Beside Us

 

FACC’s Significant Contributions to Cancer Research

 
  • Developed a limb-sparing surgical procedure in dogs with osteosarcoma, which with some adaptations has become standard of care for humans with the same cancer.
  • Studied radiation-induced late effects on normal tissues to help owners better understand the side-effects of radiation that may appear for long-term survivors.
  • Examined the application of SRT (3-5 high doses of radiation) in dogs with certain tumor types as an alternative to 30 doses of traditional lower dose radiation with similar or better outcomes.
  • Participated in the development of the first compound approved by the FDA for canine lymphoma.



To continue our groundbreaking research, we need your help. Please join our team of hope today. Together we can make a difference. Together we can work toward a cure.

Donate Today